On the stock market since 2019, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 40% below its peak. The market has trimmed its expectations for the company.
Sales run at $34.6M a year. A small number, but proof the product has real buyers.
A loss of $5.7M against $34.6M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, MCMJ sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: MCMJ is a high-risk stock — not yet profitable, and its future rides on its product catching on.